Abstract
This Letter reports our efforts towards the optimization of our previously identified series of imidazole and triazole derivatives that lead to the discovery of a series of orally active Lp-PLA2 inhibitors in C57 mice. These inhibitors are characterized by the presence of a diamine side chain in the molecules, such as 2c, 2f, and 4a. The introduction of the terminal-end amine succeeded in maintaining the in vitro activities at sub-nanomolar levels. The vivo activities could be greatly affected by variations in the two amines via modulating the metabolic stability and lipophilicity of the compounds.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Alkyl-2-acetylglycerophosphocholine Esterase / antagonists & inhibitors*
-
1-Alkyl-2-acetylglycerophosphocholine Esterase / blood
-
1-Alkyl-2-acetylglycerophosphocholine Esterase / metabolism
-
Administration, Oral
-
Animals
-
Benzaldehydes / administration & dosage
-
Benzaldehydes / chemistry
-
Benzaldehydes / pharmacology*
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Mice
-
Mice, Inbred C57BL
-
Molecular Structure
-
Oximes / administration & dosage
-
Oximes / chemistry
-
Oximes / pharmacology*
-
Rabbits
-
Recombinant Proteins / antagonists & inhibitors
-
Recombinant Proteins / metabolism
-
Structure-Activity Relationship
Substances
-
Benzaldehydes
-
Enzyme Inhibitors
-
Oximes
-
Recombinant Proteins
-
1-Alkyl-2-acetylglycerophosphocholine Esterase
-
darapladib